Welcome to AstraZeneca United States
We push the boundaries of science to deliver life-changing medicines
Advancing Health Equity through Community-Based Contributions – Announcing the ACT on Health Equity Community Solutions Challenge Recipients
Latest News from AstraZeneca US
IMFINZI® (durvalumab) plus tremelimumab demonstrated unprecedented survival in 1st-line unresectable liver cancer with 31% of patients alive at three years
IMFINZI® (durvalumab) plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer
ENHERTU® granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
AstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment with practice-changing IMFINZI® (durvalumab) and LYNPARZA® (olaparib) data at ASCO GI and GU
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities
We want to transform healthcare, change the lives of billions of people for the better and address some of the biggest healthcare challenges facing humankind. Our ambition is to stop the progress of these often degenerative, debilitating, and life-threatening conditions, achieve remission, and one day cure them.
Oncology: Start with One
At AstraZeneca, we are leading a revolution in oncology to redefine cancer care for the millions of Americans living with cancer. It’s a lofty ambition. But we know that as with every great journey, the road always starts with one—one indication that can change the course of disease for a patient, one person living with cancer that benefits from our support services, one access barrier that we can help to overcome, one system to transform in partnership with the community—and then another, building from there until success is achieved. Click below to read more about this next chapter.
If you are passionate about science, these stories will show you how the latest and most exciting projects we have been working on and the people behind them.